Actively Recruiting
Multicenter Cohort Study of AAV in Hunan of China
Led by Xiangya Hospital of Central South University · Updated on 2022-04-07
500
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
X
Xiangya Hospital of Central South University
Lead Sponsor
C
Central South University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.
CONDITIONS
Official Title
Multicenter Cohort Study of AAV in Hunan of China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fulfill 2012 criteria of ANCA associated vasculitis
- Agree to sign informed consent
You will not qualify if you...
- Do not agree to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangya hospital
Changsha, Hunan, China, 410008
Actively Recruiting
Research Team
Y
Yong Zhong, doctor
CONTACT
T
Ting Meng, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here